Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Zepbound's huge success is largely why investors are bullish on the business, and why it looks unstoppable. And as the company works on oral drugs and other weight loss treatments, it could unlock ...

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Novo is under pressure to boost its development credentials in its rivalry with Zepbound-maker Eli Lilly after a late-stage trial read-out on another next-generation obesity drug known as ...

Three Motley Fool contributors believe they've identified healthcare stocks in the latter category. Here's why they think Eli Lilly (NYSE: LLY), Intuitive Surgical (NASDAQ: ISRG), and Vertex ...